Palonosetron and Dexamethasone
ApprovedCompleted 2 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Neoplasms
Conditions
Neoplasms, Nausea, Vomiting
Trial Timeline
Oct 10, 2006 → Oct 27, 2008
NCT ID
NCT00687011About Palonosetron and Dexamethasone
Palonosetron and Dexamethasone is a approved stage product being developed by Merck for Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00687011. Target conditions include Neoplasms, Nausea, Vomiting.
What happened to similar drugs?
20 of 20 similar drugs in Neoplasms were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00687011 | Approved | Completed |
Competing Products
20 competing products in Neoplasms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ADC-1013 | Alligator Bioscience AB | Phase 1 | 19 |
| AB0024 | Gilead Sciences | Phase 1 | 29 |
| TTI-237 | Pfizer | Phase 1 | 21 |
| 852A | Pfizer | Phase 1 | 29 |
| Pemetrexed | Eli Lilly | Phase 2 | 35 |
| IMC-3C5 | Eli Lilly | Phase 1 | 29 |
| LY3295668 | Eli Lilly | Phase 1/2 | 32 |
| Galunisertib + Gemcitabine + Placebo | Eli Lilly | Phase 1/2 | 32 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 39 |
| Abemaciclib + Fulvestrant + Placebo | Eli Lilly | Phase 3 | 44 |
| LY2784544 | Eli Lilly | Phase 1 | 29 |
| enzastaurin | Eli Lilly | Phase 2 | 35 |
| Abemaciclib + Darolutamide + LHRH agonist/antagonist | Eli Lilly | Phase 1 | 29 |
| Gemcitabine + liposomal doxorubicin | Eli Lilly | Phase 3 | 40 |
| 120 mg LY2784544 | Eli Lilly | Phase 2 | 39 |
| LY4337713 | Eli Lilly | Phase 1 | 36 |
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 32 |
| LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + Fulvestrant | Eli Lilly | Phase 3 | 47 |
| VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mg | Vincerx Pharma | Phase 1 | 19 |
| VIP236 (Q3W) + VIP236 (Q2W) | Vincerx Pharma | Phase 1 | 19 |